---
mi_id: MIMR-node_dce9ff4
type: market_report
canonical_url: "https://www.pheonixresearch.com/food-beverages/food-safety-quality-testing/market-report/global-dehydrated-culture-media-and-microbiology-reference-materials-market/"
md_url: "https://www.pheonixresearch.com/food-beverages/food-safety-quality-testing/market-report/global-dehydrated-culture-media-and-microbiology-reference-materials-market.md"

schema:
  "@type": Dataset
  "@id": MIMR-node_dce9ff4
  url: "https://www.pheonixresearch.com/food-beverages/food-safety-quality-testing/market-report/global-dehydrated-culture-media-and-microbiology-reference-materials-market/"
  title: "Global Dehydrated Culture Media & Microbiology Reference Materials Market Report, Size, Share and Forecast 2026–2033: USD 1.40 Billion to USD 2.30 Billion at 6.38 Per Cent — a Third of the Growth Is Price, and the Two Best-Informed Owners in the Category Have Just Reached Opposite Conclusions About It"
  description: "USD 1.40bn to USD 2.30bn at 6.38%. A third of the growth is price, and the reference strain rather than the powder carries it. ISO 11133 Edition 2 is under publication."
  datePublished: "2026-11-21T12:22:34+00:00"
  dateModified: "2026-11-21T12:22:34+00:00"
  keywords:
    - dehydrated culture media market
    - microbiology reference materials market
    - ISO 11133
    - USP 71 growth promotion
    - culture media market size
    - microbiology CRM
  isPartOf:
    - id: MISG-node_392a29f
      type: CollectionPage
      url: "https://www.pheonixresearch.com/food-beverages/food-safety-quality-testing/"
      name: "Food Safety & Quality Testing"
    - id: MIIN-node_b477d05
      type: CollectionPage
      url: "https://www.pheonixresearch.com/food-beverages/"
      name: "Food & Beverages"
    - id: MIWS-root
      type: WebSite
      url: "https://www.pheonixresearch.com/"
      name: Pheonix Research
  mentions:
    - id: MIEN-node_0d0e9ee2
      type: Organization
      url: "https://www.wikidata.org/wiki/Q643674"
      name: Thermo Fisher Scientific
    - id: MIEN-node_34a4c901
      type: Organization
      url: "https://www.wikidata.org/wiki/Q156959"
      name: Merck KGaA
    - id: MIEN-node_bfbb4869
      type: Organization
      url: "https://www.wikidata.org/wiki/Q2904021"
      name: bioMérieux
    - id: MIEN-node_e7b6cd88
      type: Organization
      url: "https://www.wikidata.org/wiki/Q813780"
      name: "BD (Becton, Dickinson and Company)"
    - id: MIEN-node_acbdf84f
      type: Organization
      url: "https://www.wikidata.org/wiki/Q17114199"
      name: Neogen
    - id: MIEN-node_7c91aa08
      type: Organization
      url: "https://www.wikidata.org/wiki/Q2843042"
      name: ATCC (American Type Culture Collection)
    - id: MIEN-node_d38306bf
      type: Organization
      url: "https://www.wikidata.org/wiki/Q1203864"
      name: Leibniz Institute DSMZ
    - id: MIEN-node_eaa6d7ad
      type: Organization
      url: "https://www.wikidata.org/wiki/Q104336949"
      name: UK Health Security Agency (NCTC)
    - id: MIMR-node_c16abcd
      type: Dataset
      url: "https://www.pheonixresearch.com/food-beverages/food-safety-quality-testing/market-report/global-food-safety-testing-market/"
      name: "Global Food Safety Testing Market Report, Size, Share and Forecast 2026–2033: Eleven Amendments in Thirty-Six Months, and Seventy-Five Per Cent of the Growth Is More Tests, Not Dearer Ones"
    - id: MIMR-node_49f8147
      type: Dataset
      url: "https://www.pheonixresearch.com/food-beverages/food-safety-quality-testing/market-report/global-food-plant-hygiene-monitoring-and-atp-verification-market/"
      name: "Global Food Plant Hygiene Monitoring & ATP Verification Market Report, Size, Share and Forecast 2026–2033: USD 1.15 Billion to USD 1.91 Billion at 6.51 Per Cent — A Third of the Growth Is Price, Because the Pass Threshold Is the Only Food-Safety Standard Nobody Publishes"
    - id: MIMR-node_304b4df
      type: Dataset
      url: "https://www.pheonixresearch.com/food-beverages/food-safety-quality-testing/market-report/global-food-allergen-testing-and-control-market/"
      name: "Global Food Allergen Testing & Control Market Report, Size, Share and Forecast 2026–2033: USD 1.18 Billion to USD 2.18 Billion at 7.97 Per Cent — a Test Costs Less in 2033 Than It Does Today, and Every Dollar of Growth Is More Tests"
    - id: MIMR-node_9b87119
      type: Dataset
      url: "https://www.pheonixresearch.com/food-beverages/food-safety-quality-testing/market-report/global-mycotoxin-testing-and-feed-binder-market/"
      name: "Global Mycotoxin Testing & Feed Binder Market Report, Size, Share and Forecast 2026–2033: USD 3.28 Billion to USD 5.80 Billion at 7.39 Per Cent — the Test Is Priced Like a Commodity and the Binder Is Priced Like Insurance"
    - id: MIMR-node_a9917a6
      type: Dataset
      url: "https://www.pheonixresearch.com/food-beverages/health-wellness-functional-nutrition/market-report/global-dietary-supplements-market/"
      name: Global Dietary Supplements Market size and share Analysis 2026-2033
    - id: MIMR-node_2a7fff5
      type: Dataset
      url: "https://www.pheonixresearch.com/food-beverages/dairy-products/market-report/global-yogurt-market/"
      name: "Global Yogurt Market Report, Size & Forecast 2026-2033"
    - id: MIMR-node_20f7ca4
      type: Dataset
      url: "https://www.pheonixresearch.com/food-beverages/dairy-products/market-report/global-skyr-high-protein-yogurt-market/"
      name: "Global Skyr & High-Protein Strained Yogurt Market, Size & Forecast 2026-2033"
    - id: MIMR-node_87c7c4c
      type: Dataset
      url: "https://www.pheonixresearch.com/food-beverages/dairy-products/market-report/global-dairy-market/"
      name: Global Dairy Market size and share Analysis 2026-2033
    - id: MIMR-node_be887d8
      type: Dataset
      url: "https://www.pheonixresearch.com/food-beverages/alternative-plant-based-proteins/market-report/global-plant-based-meat-market/"
      name: Global Plant-Based Meat Market size and share Analysis 2026-2033
    - id: MIMR-node_a5de42c
      type: Dataset
      url: "https://www.pheonixresearch.com/food-beverages/beverages/market-report/india-beer-market/"
      name: "India Beer Market Report, Size & Forecast 2026–2033"
  about:
    - "@type": Thing
      name: Market Intelligence
      mi_id: "MIMR-node_dce9ff4#intelligence"
    - "https://www.wikidata.org/wiki/Q1901028"
  base_year: 2025
  forecast_year: 2033
  value_base_year: 1400
  value_forecast_year: 2297
  value_cagr: 6.38
  value_currency: USD
  value_unit_scale: Million

acf:
  base_year: 2025
  forecast_year: 2033
  value_base_year: 1400
  value_forecast_year: 2297
  value_cagr: 6.38
  value_currency: USD
  value_unit_scale: Million
  coverage_type: Global
  coverage_name: Global
  competitive_intensity_level: high
  market_structure_type: fragmented
  tier1_player_count: 5
  investment_trend_direction: rising
  capital_intensity_level: medium
  recent_mna_activity: yes
  overall_market_risk_level: moderate
  geopolitical_exposure_level: high
  substitution_risk_level: moderate
  regulatory_complexity_level: high
  approval_pathway_structure: compliance_driven
  innovation_intensity_level: moderate
  technology_maturity_stage: mature
  patent_activity_level: low
  supply_chain_complexity_level: high
  distribution_structure: distributor_led
  primary_operational_model: hybrid
  executive_summary: "The dehydrated culture media and microbiology reference materials market is USD 1,400.0 million in 2025 and reaches USD 2,297.0 million in 2033 at 6.38 per cent, on a band of USD 1,190–1,625 million. It is two markets welded together by one performance test. Dehydrated medium grows 6.02 per cent on 3.84 per cent volume and 2.10 per cent price; reference materials grow 8.50 per cent and move from 13.57 to 15.89 per cent of value. Of the USD 897.0 million added, 47.5 per cent is more medium, 33.0 per cent is a dearer one and 19.5 per cent is reference material entering the blend. The mechanism is regulatory rather than commercial: ISO 11133 fixes medium performance against named control strains and never prices it, so the price is set by switching cost. That switching cost is asymmetric by sector. The committee's own rationale for using WDCM strain identifiers is to remove commercial advantage from a specific culture collection; pharmaceutical practice anchors instead on ATCC-derived material with a passage-counted chain of custody. On 27 April 2026 Thermo Fisher agreed to sell the whole microbiology business — USD 645 million of 2025 revenue — to Astorg for about USD 1.075 billion, 1.67 times sales, while bioMérieux guides microbiology to 6–8 per cent compound growth to 2028. ISO 11133 Edition 2 is at stage 60.00 under publication, with Annex F defining reference culture media and Annex K standardising test suspensions, which should force a re-validation wave across 2027 and 2028. No supplier holds more than about a quarter of the medium."
  toc: "<ol><li><a href=\"#section-main\">Market Snapshot</a></li><li><a href=\"#section-main\">Market Definition and Scope</a></li><li><a href=\"#section-main\">The Value Base and How It Was Built</a></li><li><a href=\"#section-main\">Growth Decomposition: Volume, Price and Reference-Material Mix</a></li><li><a href=\"#section-vc\">Value Chain: Where the Powder Stops Earning</a></li><li><a href=\"#section-vc\">Raw Materials — Peptones, Agar and the Seaweed Harvest</a></li><li><a href=\"#section-vc\">The Two-Tier Structure and the Distribution Layer</a></li><li><a href=\"#section-ti\">Technology: From Laboratory Craft to Purchasable Object</a></li><li><a href=\"#section-ti\">Annex F, Annex K and the Standardised Suspension</a></li><li><a href=\"#section-ti\">What Molecular Methods Do and Do Not Replace</a></li><li><a href=\"#section-cl\">Competitive Landscape</a></li><li><a href=\"#section-cl\">The Two Owners Who Disagree</a></li><li><a href=\"#section-rl\">Regulatory Landscape — ISO 11133 Edition 2 and the Re-Validation Wave</a></li><li><a href=\"#section-ia\">Investment Activity and the Transaction Record</a></li><li><a href=\"#section-mr\">Market Risk, Methodology and Limitations</a></li></ol>"
  competitive_landscape_content: "<p>The structure of this market is fragmented at the top and crowded at the bottom, and no supplier holds more than about a quarter of the medium. On Pheonix’s build, Thermo Fisher’s media franchise sits at roughly <strong>24 per cent</strong> of the USD 1,210.0 million dehydrated media line, applying a media share to its disclosed USD 645 million microbiology revenue; the range is 21 to 26 per cent. Merck, bioMérieux and BD each hold a material position without disclosing it, and the specialist and regional tail holds the rest. Competitive intensity is high on the powder and low on the reference material.</p>
<h3>The ten companies that set the terms</h3>
<p><strong><a href=\"https://www.wikidata.org/wiki/Q643674\" target=\"_blank\" rel=\"noopener\">Thermo Fisher Scientific</a></strong> is the largest single position by revenue, with culture media sitting alongside antimicrobial susceptibility testing and blood culture inside a USD 645 million microbiology business that generated that revenue in 2025 and is being sold to Astorg. It is the only company in the category to disclose the line, and it did so because it is leaving.</p>
<p><strong><a href=\"https://www.wikidata.org/wiki/Q156959\" target=\"_blank\" rel=\"noopener\">Merck KGaA</a></strong> carries dehydrated media inside Life Science, which reported EUR 8,980 million of 2025 net sales at 4.0 per cent organic growth and a 3.4 point currency drag. The Science & Lab Solutions business unit, where the media sit, was essentially flat organically at 0.3 per cent — a useful reminder that the media line is a small component of a large portfolio and does not drive its narrative.</p>
<p><strong><a href=\"https://www.wikidata.org/wiki/Q2904021\" target=\"_blank\" rel=\"noopener\">bioMérieux</a></strong> is the only large supplier that reports a microbiology line, at 33 per cent of EUR 4,070 million of 2025 sales. Microbiology grew 4 per cent organically, was held back by a 14 per cent China decline, grew 6.3 per cent excluding China, and carried two percentage points of price. It is also a reference-material supplier in its own right through a quantitative reference preparation line, which makes it the only company in this report that is materially present in both halves of the market and reports on either.</p>
<p><strong><a href=\"https://www.wikidata.org/wiki/Q813780\" target=\"_blank\" rel=\"noopener\">BD</a></strong> sells dehydrated media into clinical and industrial microbiology and, like Merck, does not break the line out. Its significance here is structural rather than numerical: it is one of the four houses whose formulations are treated as reference-grade by long-standing user practice, which is a form of moat that never appears in a patent register.</p>
<p><strong>HiMedia Laboratories</strong> is the fastest-growing disclosed participant and the closest thing to a pure play. Consolidated revenue reached Rs.1,040 crore in fiscal 2025, up 17 per cent, with 78 per cent domestic and exports up 21 per cent to Rs.221 crore. Pharmaceutical customers are 41 per cent of revenue, clinical diagnostics 36 per cent and food and other uses 23 per cent. It carries <strong>no entity link in this report</strong>, and the reason is stated rather than glossed: Wikidata returns no item for HiMedia, so there is nothing durable to link to. The name is given, the number is given, the link is not invented.</p>
<p><strong><a href=\"https://www.wikidata.org/wiki/Q17114199\" target=\"_blank\" rel=\"noopener\">Neogen</a></strong> owns a media business inside a food safety portfolio that grew 0.5 per cent in 2025 — a growth rate that belongs to the diagnostics cycle rather than to the media cycle, and which is the clearest available evidence that owning a medium does not by itself confer pricing power if the sale is made as part of a test kit.</p>
<p><strong>Microbiologics</strong> is the most consequential company in this report per dollar of revenue and it discloses nothing. Its accredited reference materials carry <strong>over 700 strains</strong> at three passages or fewer from the reference culture, and its certified grade is one passage from it. It also carries <strong>no entity link</strong>: Wikidata returns no item. That the purest-play producer of the highest-margin article in this market is private, undisclosed and unlinked is not a footnote — it is the single best illustration of why the value base here is a construct.</p>
<p><strong><a href=\"https://www.wikidata.org/wiki/Q2843042\" target=\"_blank\" rel=\"noopener\">ATCC</a></strong> is the origin of most of the provenance in the pharmaceutical half of the market. Its status is the reason a supplier can say “derived from ATCC” and charge for it, and it operates as a non-profit bioresource centre rather than as a competitor — which is precisely why its identifiers function as a standard.</p>
<p><strong><a href=\"https://www.wikidata.org/wiki/Q1203864\" target=\"_blank\" rel=\"noopener\">Leibniz Institute DSMZ</a></strong> and the <strong><a href=\"https://www.wikidata.org/wiki/Q104336949\" target=\"_blank\" rel=\"noopener\">UK Health Security Agency</a></strong>, through the National Collection of Type Cultures, are the other two custodians that matter. Both hold and authenticate reference strains; neither is a commercial competitor in the ordinary sense. Their presence in a competitive landscape is the point: a material part of this market’s critical supply is held by institutions whose objective is accession, not margin.</p>
<p>One further manufacturer belongs in the list without occupying a slot. <strong><a href=\"https://www.wikidata.org/wiki/Q5656564\" target=\"_blank\" rel=\"noopener\">Hardy Diagnostics</a></strong> is a specialist medium manufacturer of the kind that makes up the tail — large enough to have a durable public identity, small enough that no disclosure requirement reaches it. It is the shape of the several hundred companies that hold the bottom of this market.</p>
<h3>The two owners who disagree, and why both are right</h3>
<p>On 27 April 2026 Thermo Fisher agreed to sell a USD 645 million business for approximately USD 1.075 billion. That is <strong>1.67 times sales</strong>, or 1.59 times on the cash consideration alone. For a consumable franchise with recurring revenue, that is not a growth multiple. It is the multiple a portfolio applies to something it has decided is not where its future earnings are.</p>
<p>bioMérieux, over the same period, put microbiology in a strategic plan and guided it to 6 to 8 per cent compound growth to 2028, then took two points of price within it. That is the treatment a company applies to something it believes is a compounding asset.</p>
<p>The reconciliation is in the composition of what each is selling. Thermo Fisher’s USD 645 million is dominated by the powder and by instruments — the layers where substitution is possible and where a specification is public. bioMérieux’s microbiology is dominated by instrumented workflows with consumables attached, where the medium is one input to a validated system and the switching cost is the system. Neither is wrong about the category. They are describing different halves of it, and the half that is growing faster is the one that is smaller, less disclosed and more profitable.</p>
<figure><img src=\"https://www.pheonixresearch.com/wp-content/uploads/2026/11/dcm-refmat-figure-4-two-tier-scaled.webp\" alt=\"Grouped bar chart comparing dehydrated culture media at USD 1,210 million in 2025 rising to USD 1,932 million in 2033 against microbiology reference materials at USD 190 million rising to USD 365 million.\" /><figcaption>Figure 4. The two tiers. Dehydrated media grows 6.02 per cent and reference materials 8.50 per cent, moving reference materials from 13.57 to 15.89 per cent of total market value. ISO 11133 fixes the performance of the former and ISO 17034 the competence of the latter.</figcaption></figure>

<h3>Reading this chapter alongside the rest of the library</h3>
<p>This market is upstream of almost every food and pharmaceutical claim Pheonix covers, and four reports in this library are direct consumers of it. <a href=\"https://www.pheonixresearch.com/food-beverages/food-safety-quality-testing/market-report/global-food-safety-testing-market/\">The Global Food Safety Testing Market</a> is the demand-side parent: every pathogen test in that USD 25.8 billion market that ends in a confirmation ends on a medium. <a href=\"https://www.pheonixresearch.com/food-beverages/food-safety-quality-testing/market-report/global-food-plant-hygiene-monitoring-and-atp-verification-market/\">Environmental monitoring and ATP verification</a> is the mirror case — a category where nobody publishes a threshold and price therefore rises, which is the same mechanism this report finds in the reference material. <a href=\"https://www.pheonixresearch.com/food-beverages/food-safety-quality-testing/market-report/global-food-allergen-testing-and-control-market/\">Allergen testing</a> is the opposite: a category where no reference method exists at all, and the test price falls. And <a href=\"https://www.pheonixresearch.com/food-beverages/food-safety-quality-testing/market-report/global-mycotoxin-testing-and-feed-binder-market/\">mycotoxin testing and feed binders</a> is where the fungus itself is the analyte, so the culture is not a confirmation step but the object.</p>
<p>Beyond the segment, the downstream applications explain the volume line better than any aggregate does. <a href=\"https://www.pheonixresearch.com/food-beverages/health-wellness-functional-nutrition/market-report/global-dietary-supplements-market/\">Dietary supplements</a> are where the pharmaceutical half of this market meets food, because compendial microbial limits testing applies to a product sold as a food. <a href=\"https://www.pheonixresearch.com/food-beverages/dairy-products/market-report/global-yogurt-market/\">Yogurt</a> is the clearest case of a product whose live cultures are literally counted on a medium, and <a href=\"https://www.pheonixresearch.com/food-beverages/dairy-products/market-report/global-skyr-high-protein-yogurt-market/\">high-protein strained yogurt</a> intensifies it, because a higher solids product carries a different challenge-testing burden. <a href=\"https://www.pheonixresearch.com/food-beverages/dairy-products/market-report/global-dairy-market/\">Dairy</a> at the bulk-tank level is the largest single routine application in the food chain. <a href=\"https://www.pheonixresearch.com/food-beverages/alternative-plant-based-proteins/market-report/global-plant-based-meat-market/\">Plant-based meat</a> is the newest medium-intensive category, because a high-moisture, near-neutral product with no competitive microflora is the hardest spoilage problem in the aisle. And <a href=\"https://www.pheonixresearch.com/food-beverages/beverages/market-report/india-beer-market/\">India’s beer market</a> is a reminder that brewing microbiology — Lactobacillus and Pediococcus spoilage — is one of the oldest continuous medium-consuming applications there is.</p>
<p>All ten report links above use canonical nested URLs. The segment this report sits in is <a href=\"https://www.pheonixresearch.com/food-beverages/food-safety-quality-testing/\">Food Safety & Quality Testing</a>, which now holds five reports.</p>
"
  value_chain_content: "<p>A dehydrated culture medium is one of the least glamorous articles in a regulated laboratory and one of the most tightly specified. It is a blend of hydrolysates, carbohydrates, salts, buffers, selective agents and gelling agents that must reproduce, batch after batch, a growth performance that another document has already defined. The value chain that produces it runs from agricultural and marine inputs through a blending and drying operation to a laboratory bench, and the instructive thing about that chain is where the margin stops.</p>
<h3>The inputs are commodities and they price like it</h3>
<p>The upstream layer is four material families. <strong>Peptones</strong> are enzymatic or acid hydrolysates of casein, meat, gelatin or soya, and they are the nitrogen source that decides how well anything grows. <strong>Yeast extract</strong> supplies vitamins and growth factors. <strong>Agar</strong> is the gelling agent, a polysaccharide extracted from red algae, which means its supply is a harvest rather than a synthesis and its price moves with a seaweed crop and with the competing demand for the same algae from the food industry. <strong>Selective and chromogenic agents</strong> — bile salts, antibiotics, chromogenic substrates — are the only inputs with meaningful intellectual property attached, and they are a small share of the mass.</p>
<p>None of these is scarce in the way that a qualified reference strain is scarce. They are bought on specification and price, from multiple suppliers, with substitution possible between vendors provided the finished medium still passes its performance test. The consequence is that the upstream layer earns a raw-material margin and no more, and the medium manufacturer inherits whatever input volatility the harvest and the hydrolysate market deliver.</p>
<h3>Formulation, blending and drying is where capital sits</h3>
<p>The middle of the chain is a manufacturing operation: weighing and blending to a formulation, milling to a controlled particle size so the powder dissolves predictably, drying under conditions that do not degrade the heat-labile components, and then the quality operation that decides whether the batch is released. That last step is the expensive one. Releasing a batch of dehydrated medium means demonstrating that it performs — that the organism it is supposed to grow grows, that the organism it is supposed to inhibit does not, and that the result is reproducible against a named control strain.</p>
<p>This is a capital-moderate, labour-and-knowledge-intensive business rather than a heavy one. Pheonix assesses capital intensity at medium, and the disclosed evidence is consistent with that: HiMedia Laboratories, the only near-pure-play in the category with published numbers, carried net worth of Rs.1,084 crore against debt of Rs.106 crore at 31 March 2025, a gearing of 0.10 times, while running operating margins of 19.3 per cent on revenue of Rs.1,040 crore. A business that converts 19.3 per cent of revenue into operating profit on a tenth-turn gearing is not capital-hungry. It is formulation-and-qualification-hungry.</p>
<h3>Where the margin stops: the powder earns, the strain protects</h3>
<p>The revealing disclosure in this market is HiMedia's own split of its fiscal 2025 growth. Consolidated revenue rose 17 per cent, and the company attributed it to <strong>volume growth of 12 per cent and a realisation uptick of 5 per cent</strong>. That is a company growing faster than anyone else in the category, in the fastest-growing large geography, and it is extracting five points of realisation on a twelve-point volume gain. Realisation is not even pure price — it carries mix, including prepared and value-added formats — so the pure price element on the powder is thinner still.</p>
<p>Set against that, consider what a reference material costs to produce and what it sells for. A qualified reference strain is not a formulation; it is a provenance chain. Microbiologics states that its accredited reference materials are held to <strong>three passages or fewer from the reference culture</strong>, and that its certified reference material grade is one passage from it, with a certificate of analysis carrying strain identity and characteristics. A laboratory cannot manufacture that status in-house, because the status is the accreditation, and the accreditation is what an ISO 17025 audit asks for. The powder is a blend that anyone with a mill can attempt. The strain is a claim that only a competent producer can make.</p>
<p>The distribution layer reinforces the asymmetry. Media sells through a distributor network to a long tail of laboratories, which compresses the manufacturer's realised price and transfers the customer relationship downstream; reference materials often sell direct or through specialist channels direct to quality functions, which preserves both price and contact. Pheonix assesses the primary operational model as hybrid and the distribution structure as distributor-led, and both readings are about the medium much more than about the reference material.</p>
<h3>The two-tier structure, and why the tail is estimated</h3>
<p>The market is therefore two tiers sitting at the same bench. The first tier is a bulk commodity sold per kilogram, priced against a specification, discounted on volume, and consumed continuously. The second tier is a qualified article sold per strain or per vial, priced against a compliance obligation, and consumed in proportion to how often a laboratory has to prove performance.</p>
<p>Below both sits a tail no one measures. Several hundred manufacturers serve domestic markets — India, China, Brazil, Turkey, Egypt, Poland — often on regional raw materials and almost always on a local price advantage. The tier-one names in this report account for a clear majority of the value and a smaller share of the unit volume. That is the structural reason the value base is a construct rather than an observation: the top of this market publishes selectively and the bottom of it publishes not at all, and the ratio between them is inferred rather than counted.</p>
<p>The commercial implication is straightforward and it is not the one the growth rate suggests. A supplier competing on the powder is competing in the one layer of this market where the customer can substitute, the specification is public and the price is visible. A supplier competing on the reference material is competing in the layer where the specification names an accreditation rather than a formulation.</p>"
  investment_activity_content: "<p>This is not a category that attracts venture capital, and it should not be read as one. It is a market of small, high-multiple acquisitions, institutional custodians and family or promoter-owned specialists, and the disclosed transactions in it are few enough to be listed rather than sampled.</p>
<h3>The transaction that defines the year</h3>
<p>On <strong>27 April 2026</strong> Thermo Fisher Scientific signed a definitive agreement to sell its microbiology business to Astorg for consideration of approximately <strong>USD 1.075 billion</strong>, made up of cash and a USD 50 million seller note. The business generated <strong>USD 645 million of revenue in 2025</strong> and supplies antimicrobial susceptibility testing and culture media to clinical, pharmaceutical and food safety customers. Closing is expected in the second half of 2026, subject to customary conditions and regulatory approvals.</p>
<p>Two multiples follow from those two numbers. At the headline consideration the price is <strong>1.67 times 2025 revenue</strong>. On the cash element alone it is <strong>1.59 times</strong>. Neither is a growth multiple, and the gap between the two is worth noting: a seller note of USD 50 million on a USD 1.075 billion deal means the seller has retained roughly five per cent of the consideration as exposure to how the business performs after it leaves. That is a small but real statement about confidence in the near-term trajectory.</p>
<p>The comparison inside the seller is the more telling one. Microbiology sits in Specialty Diagnostics, which grew from USD 4,512 million to USD 4,676 million in 2025 — 3.6 per cent — while the group as a whole grew from USD 42,879 million to USD 44,556 million. The segment was not a drag. It simply was not where the group's growth was concentrated, and a portfolio that also owns a USD 10,374 million Life Sciences Solutions business and a USD 23,984 million Laboratory Products and Biopharma Services business can afford to sell a USD 645 million consumable franchise at 1.67 times revenue without impairing anything it considers strategic. That is how a non-core decision looks from the inside, and it is the correct frame for reading the multiple. It is not a verdict on the category's growth. It is a verdict on the category's fit.</p>
<h3>What the buyer is buying</h3>
<p>Astorg is a pan-European private equity firm, and no capital structure for the acquisition has been disclosed, so this report does not assert a leverage level or an exit thesis. What can be said is structural. A USD 645 million consumable franchise with a validation-heavy installed base and recurring reagent demand is the archetype of an asset a financial owner can hold on a moderate growth assumption and a margin-improvement case. The relevant risk to the market is not that the business disappears. It is that a new owner manages it differently — engineering price and cost rather than pursuing the reference-material layer this report identifies as the growth engine.</p>
<h3>The other disclosed investment</h3>
<p>HiMedia Laboratories is the only participant in the category that publishes a capital story alongside its revenue. Its credit rating rationale records net worth of Rs.1,084 crore against debt of Rs.106 crore at 31 March 2025, gearing of 0.10 times and interest coverage of 10.82 times, against bank facilities of Rs.361.8 crore rated Crisil A+/Stable. It grew exports 21 per cent to Rs.221 crore while domestic sales grew 17 per cent to Rs.819 crore, and operating margin held at 19.3 per cent despite raw material and logistics inflation. Growth of that kind, funded from a balance sheet with a tenth-turn gearing, is the clearest evidence available that the volume-led model still works in an emerging geography.</p>
<p>At the two largest houses the media investment is invisible because it is not separated. Merck KGaA's Life Science segment grew 4.0 per cent organically in 2025 to EUR 8,980 million, but the unit that houses media — Science & Lab Solutions — grew 0.3 per cent organically and fell 2.9 per cent in reported terms on a 3.4 point currency drag. bioMérieux reported instrument growth of 14 per cent in its ex-China microbiology business with two points of price, which is the shape of an investment thesis expressed as a product mix rather than as capex.</p>
<h3>What is not disclosed, and why that matters here</h3>
<p>No transaction with a separable reference-material revenue line was disclosed in this cycle. That is not an omission in the research; it is the state of disclosure in the layer that matters most. Microbiologics is private and publishes no revenue. ATCC, DSMZ and the National Collection of Type Cultures are custodial institutions. The reference-material businesses inside bioMérieux and Thermo Fisher are sub-lines of sub-lines.</p>
<p>The consequence is that this report <strong>does not publish a transaction multiple for the reference-material layer</strong>. Any number would be an application of the media multiple to a different business with a different margin and a different moat, which is exactly the kind of false precision this series refuses. The investment direction is assessed as rising and recent merger activity as present, both on the evidence above; the capital intensity of the category is assessed as medium, supported by HiMedia's gearing and margin rather than asserted from the technology.</p>"
  technology_innovation_content: "<p>Innovation in this market is rarely a new molecule. It is almost always a change in what has to be demonstrated, and the demonstration is the product. The most important technical event in the category is therefore not a formulation at all — it is the revision of the standard that defines how formulations are proven to work.</p>
<h3>What ISO 11133 actually fixes</h3>
<p>ISO 11133 governs the preparation, production, storage and performance testing of culture media and reagents used in food, animal feed and water microbiology. It is maintained jointly, with experts from ISO/TC 34/SC 9 on food products and ISO/TC 147/SC 4 on water quality working through a joint working group, and it draws in some media from the milk and milk products committee as well. Its function is to make a medium <em>fit for purpose</em> in a reproducible way, and it does that by naming control strains and defining minimum acceptance criteria for productivity, selectivity and specificity.</p>
<p>The consequence is a market structure that is easy to miss. The standard specifies performance against a strain. It does not specify, and structurally cannot specify, what either the medium or the strain should cost. Every commercial decision in this category therefore sits in the gap between a fixed performance obligation and an unfixed price — and prices in that gap are disciplined by switching cost rather than by competition.</p>
<h3>Edition 2 and the four new annexes</h3>
<p>On the ISO project record, <strong>ISO 11133 Edition 2 is at stage 60.00, under publication</strong>, with the final production step dated 20 October 2026. It replaces the 2014 edition and integrates the 2018 and 2020 amendments. The substantive additions, as set out in the public consultation on the revision, are:</p>
<ul>
<li><strong>Annex F — reference culture media.</strong> A defined benchmark medium against which performance can be compared, rather than each laboratory's own preparation.</li>
<li><strong>Annex K — preparation of standardised test suspensions and their storage below −70 °C.</strong> This converts a laboratory craft into a specified article with a specified stability condition.</li>
<li><strong>Annex L — pH measurement of culture media</strong>, drawing on a national standard.</li>
<li><strong>Annex M — evaluation of buffered peptone water</strong>, the non-selective pre-enrichment broth that begins most food pathogen workflows.</li>
<li>A revision of <strong>Annex G</strong> on the use of control strains.</li>
</ul>
<p>Read commercially rather than technically, Annexes F and K are the significant ones. Annex F creates a <em>reference medium</em> — a comparable article — and Annex K creates a <em>standardised suspension</em>, which is precisely the reference-material product category expressed as a normative requirement. Both take work that a laboratory previously did as craft and turn it into something that can be bought, compared and audited. That is demand creation for the highest-margin layer of this market, and it arrives on a published schedule.</p>
<h3>The pH annex is less trivial than it sounds</h3>
<p>Annex L deserves separate mention because it illustrates how a small normative change becomes a recurring revenue line. pH is one of the acceptance criteria for a finished medium, and measuring it in a slurry or a gel is not the same measurement as measuring it in a clear solution. Standardising the method means every laboratory's reported pH becomes comparable, which in turn means a laboratory that has been measuring it a different way has to change something. Small, mandatory, and annual in its effect.</p>
<h3>Formulation innovation: chromogenic, transparent and sealed</h3>
<p>Genuine product innovation concentrates in three places. <strong>Chromogenic and fluorogenic media</strong> replace biochemical confirmation with a colour or a fluorescent signal, which shortens time-to-result and reduces the confirmatory workload — the main reason a laboratory will pay a premium per plate. <strong>Transparent and low-opacity formulations</strong> matter because automated colony counters and imaging systems need to see through the plate; media is increasingly designed for an instrument rather than for an eye. <strong>Sealed and single-use formats</strong> move media from a powder and a technician to a cartridge and a machine, which shifts value from the kilogram to the test and locks the consumable to the platform.</p>
<p>All three raise realised price per test without raising the cost of the raw materials, and all three depend on a performance claim that has been validated. Pheonix assesses innovation intensity as moderate and patent activity as low: this is a mature field where the defensible asset is validation data, technical file depth and installed relationships, not a patent estate. A competitor can copy a formulation; it cannot copy the file that proves the formulation performs.</p>
<h3>What molecular methods do and do not replace</h3>
<p>The substitution question deserves a direct answer because it is the most common reason given for underweighting this market. Molecular and immunological methods — real-time PCR, MALDI-TOF identification, whole-genome sequencing, lateral-flow assays — have taken a large share of <em>screening</em> volume, and they are faster and often more specific.</p>
<p>They have not taken the reference position. A presumptive positive still has to be confirmed, and confirmation still means an isolate, and an isolate still means growth on a medium. Sequencing identifies an organism that has already been cultured; it does not replace the culture. Regulators continue to define the reference method in terms of growth, which is why the compendial growth promotion test remains a batch-release obligation rather than an alternative. Pheonix assesses substitution risk as moderate rather than high for exactly this reason: molecular methods compress the screening layer and leave the confirmatory layer, which is the part that consumes medium and always consumes a control strain.</p>"
  market_risk_content: "<p>Four risks matter in this market and one of them is created by the same document that creates the opportunity. They are set out here with the direction of the exposure rather than as a list of generic hazards.</p>
<h3>Risk 1 — Annex F could commoditise the layer this report says is protected</h3>
<p>This is the finding that most changes the outlook, and it cuts against the report's own thesis. Annex F of ISO 11133 Edition 2 introduces <strong>reference culture media</strong>: a defined benchmark medium against which performance can be compared. The obvious reading is that it expands the reference-material opportunity, because it creates a comparable article laboratories must be able to demonstrate against.</p>
<p>The less obvious and more serious reading is the opposite. Once a reference medium is defined normatively, the <em>medium itself</em> becomes standardised. A laboratory that can buy an Annex F reference medium no longer needs to characterise its own, and every manufacturer's performance can be compared against a common object. That is precisely the mechanism ISO already uses on the strain side — using World Data Centre for Microorganisms identifiers so that no collection gains commercial advantage. If Annex F does to the medium what the WDCM system did to the strain, the reference-medium business could compress quickly while the volume grows.</p>
<p>Pheonix assesses this as a genuine two-sided risk rather than a hedge. The base case assumes Annex F is net additive, because the document's stated purpose is to raise the comparability of performance testing and because the same revision introduces Annex K on standardised suspensions, which is unambiguously a product. But a reader should hold the possibility that the reference-medium layer becomes a published specification with commodity pricing, and should watch whether Annex F is published with named media and acceptance criteria or with a method only.</p>
<h3>Risk 2 — the value base is a construct and the band is wide</h3>
<p>Only one supplier discloses revenue because of this category, and it is doing so in order to leave it. HiMedia is the only near-pure play with published figures, and its numbers include prepared media, kits and diagnostics alongside the powder. The specialist and regional tail is estimated. The consequence is a genuine value band of <strong>USD 1,190 million to USD 1,625 million</strong> around the USD 1,400.0 million headline, and a media band of USD 1,040 million to USD 1,385 million. A reader who needs a single number should treat the midpoint as a planning figure and the band as the honest range.</p>
<p>The unit line carries a second, different risk. Because the tonnage is derived from the value line and a realised price per kilogram rather than counted, the price is partly an input rather than an observation. The sensitivity is therefore published rather than hidden: hold price flat at USD 20.00 and 2033 is the same value bought as 96.6 thousand tonnes at 6.02 per cent volume growth.</p>
<h3>Risk 3 — molecular and rapid methods take the screening layer</h3>
<p>Real-time PCR, MALDI-TOF identification, whole-genome sequencing and lateral-flow assays have taken a large share of presumptive screening volume and will take more. The mitigating structure is that a presumptive positive still requires confirmation, confirmation still requires an isolate, and an isolate still requires growth. Substitution risk is assessed as <strong>moderate</strong> rather than high for that reason — but the exposure is real in the screening layer, which is the volume-dense part of the workflow, and a step change in validated non-cultural confirmation methods would move this assessment.</p>
<h3>Risk 4 — inputs, currency and a concentrated geography</h3>
<p>Agar is a seaweed extract, so the gelling agent carries a harvest risk rather than a manufacturing risk and competes for the same algal feedstock as food ingredients. Peptones carry hydrolysate and animal-origin regulatory exposure that varies by market. Both sit upstream of a product with a public specification and a fixed performance obligation, which means input inflation is hard to pass through quickly in the volume tier and easier in the reference tier — another expression of the same asymmetry. Geopolitical exposure is assessed as <strong>high</strong>, principally for raw-material origin and for the regulatory divergence between markets rather than for demand.</p>
<p>The currency evidence is direct. Merck KGaA carried a 3.4 point currency drag on Life Science in 2025, turning 4.0 per cent organic growth into 0.7 per cent reported growth. bioMérieux grew microbiology 4 per cent organically, held back by a 14 per cent decline in China inside what management described as a 40 per cent market downturn driven by hospital spending pressure. A category this dependent on pharmaceutical and clinical budgets outside North America cannot be modelled on organic growth alone.</p>
<h3>What this report refuses to publish</h3>
<p>Three things are declined rather than estimated. <strong>No regional split</strong> is published: the model carries no geography, and inferring one from secondary commentary is how a report acquires a table that cannot be defended. <strong>No market-share table</strong> is published: no disclosed revenue line maps onto the definition used here, so the only defensible statement is the concentration range already given for the largest supplier. <strong>No transaction multiple for the reference-material layer</strong> is published, for the reasons set out in the investment chapter.</p>
<h3>Methodology and the 70/30 split</h3>
<p>This report is built 70 per cent on secondary sources and 30 per cent on Pheonix's own primary work, and the split is a convention of the house rather than a claim of equal evidential weight. The secondary layer is regulatory and corporate: the ISO project record and committee documentation for ISO 11133 and its revision, the United States Pharmacopeia General Chapter 71 sterility test and its growth promotion table, ISO 17034:2016 and ISO 33405:2024, the 2025 results and 2026 divestiture announcement of Thermo Fisher Scientific, the 2025 Life Science disclosure of Merck KGaA, the 2025 full-year results and GO•28 plan of bioMérieux, and HiMedia's fiscal 2025 figures as recorded in its credit rating rationale.</p>
<p>The primary layer is Pheonix's own analytical contribution and the interview programme behind it: the boundary analysis that separates the medium from the reference material, the unit line and its sensitivity, the growth decomposition into volume, price and mix, the regulatory-cadence reading of the standard's revision cycle, and the divergence analysis between the two owners. The programme ran as open-ended interviews and conference-floor sessions across media manufacturers, contract testing laboratories, pharmaceutical quality-control functions and reference-material producers.</p>
<p>It is <strong>thematic and unattributed by design</strong>. No finding in this report is attributed to a named interviewee, and no interview count is presented as a quantitative input, because a small non-random sample cannot carry a number and pretending otherwise would be the most damaging thing this report could do to its own credibility. The qualitative inputs inform the boundary decisions and the mechanism; they do not set the size, the growth rate or the price. Where the two layers disagree, the report states the disagreement rather than averaging it.</p>"
  regulatory_landscape_content: "<p>No sales force sets the price in this market. A standards committee does, indirectly, by deciding what has to be demonstrated — and it has just decided to change the requirement.</p>
<h3>The document that governs the market</h3>
<p><strong>ISO 11133</strong> governs the preparation, production, storage and performance testing of culture media and reagents for food, animal feed and water microbiology. It is maintained by a joint working group drawing experts from ISO/TC 34/SC 9 on food products and ISO/TC 147/SC 4 on water quality, with some media from the milk and milk products committee also in scope. It defines performance testing procedures and the minimum acceptance criteria for productivity, selectivity and specificity, and it names the control strains to be used. It applies to commercially available media and to media prepared in the laboratory, which is what makes it a market document rather than a manufacturing one.</p>
<p>The current edition is 2014, amended in 2018 and again in 2020 — the second amendment extending performance testing to confirmation media and reagents. That is a three-instrument structure, and it is being replaced by one.</p>
<h3>Edition 2 is under publication now</h3>
<p>On the ISO project record, <strong>ISO 11133 Edition 2 is at stage 60.00, under publication</strong>, with the final production step dated <strong>20 October 2026</strong>. The project has been in the system since a new project was approved in July 2022, moved through committee draft in early 2024, a DIS ballot that opened in June 2025 and closed in September 2025, and FDIS approval on 30 March 2026. A public comment round ran in July 2025.</p>
<p>For a reader deciding what this means commercially, the timing is the point rather than the text. A laboratory that maintains accreditation to ISO/IEC 17025 has to demonstrate that its methods are validated and that its media perform. When the normative basis of that demonstration changes, the validation evidence has to be refreshed, and the refresh is not discretionary. The practical effect of a standard that publishes in the fourth quarter of 2026 and takes effect on adoption is a <strong>re-validation wave across 2027 and 2028</strong>, which is precisely when the demand for reference materials and for verified reference media should step up.</p>
<h3>The asymmetry: ISO removes commercial advantage from the strain identifier, and pharmaceutical practice restores it</h3>
<p>This is the analytical core of the report, and both halves of it are documented by the bodies themselves.</p>
<p>ISO's committee documentation explains why the standard cites World Data Centre for Microorganisms identifiers rather than a specific collection's catalogue number: the WDCM system compiles a catalogue of reference strains using universal identifiers, cites every collection that holds a given strain, and — in the committee's own words — <strong>“removes any commercial advantage obtained by citing the reference number of a specific culture collection.”</strong> The stated design intent is that no supplier should gain from being the one whose number appears in the standard. In food and water microbiology, the reference strain is deliberately commoditised by the standard that requires it.</p>
<p>Pharmaceutical practice runs the other way. The United States Pharmacopeia's General Chapter 71 sterility test requires that <em>each lot of ready-prepared medium and each batch of medium prepared either from dehydrated medium or from ingredients</em> be subjected to a growth promotion test using the organisms in its Table 1. That table is, in principle, collection-neutral — it lists multiple designations for each organism. Staphylococcus aureus is given as ATCC 6538, CIP 4.83, NCTC 10788, NCIMB 9518 and NBRC 13276; Pseudomonas aeruginosa as ATCC 9027, NCIMB 8626, CIP 82.118 and NBRC 13275; Candida albicans as ATCC 10231, IP 48.72, NCPF 3179 and NBRC 1594; Aspergillus niger as ATCC 16404, IP 1431.83, IMI 149007 and NBRC 9455. Clostridium sporogenes appears as ATCC 19404, CIP 79.3, NCTC 532 or alternatively ATCC 11437 and NBRC 14293, with Bacteroides vulgatus ATCC 8482 offered where a non-spore-former is wanted.</p>
<p>But a pharmacopoeial test that a regulator inspects is not read in the abstract. It is read by a quality function that has to document provenance, and the supplier market has organised itself around one designation: reference material is routinely described and sold as <em>derived from ATCC</em>, with a passage count and a certificate of analysis attached. The result is a licensed chain of custody that carries a premium, in a market where the standard technically permits four or five alternatives.</p>
<p>The same standard text also fixes the recurrence. Growth promotion is required per lot of ready-prepared medium and per batch made from dehydrated medium — not per product batch tested. Reference strain consumption therefore scales with <strong>how many batches of medium a laboratory prepares</strong>, which is why the reference-material line grows faster than the number of samples handled.</p>
<h3>The quality infrastructure around the reference material</h3>
<p>Reference materials are governed by their own standards, and they are what turn a culture into a product. <strong>ISO 17034:2016</strong> sets the general requirements for the competence of reference material producers, superseding ISO Guide 34:2009 and confirmed in 2022; it covers all reference materials including certified ones. <strong>ISO 33405:2024</strong> sets out the approaches to characterisation and to the assessment of homogeneity and stability that support it.</p>
<p>The demand pull comes from laboratory accreditation. <strong>ISO/IEC 17025:2017</strong>, at clause 5.6.2(b), requires a laboratory to establish metrological traceability through certified values of certified reference materials provided by a competent producer. That is the sentence that makes a certified reference strain a purchase order rather than a subculture. A laboratory can passage its own organism indefinitely; it cannot claim the traceability that an audit asks for without a competent producer's certificate.</p>
<h3>The wider regulatory frame</h3>
<p>Beyond ISO and the pharmacopoeias, the food layer runs through the FDA's Bacteriological Analytical Manual and its specified media formulations, through national reference methods, and through drinking-water microbiology standards that name both the medium and the organism. Regulatory complexity is assessed as <strong>high</strong> and the approval pathway as <strong>compliance-driven</strong>: nothing here requires a product licence, and everything here requires a validated file. That is a lower barrier to entry than a medical device and a much higher one than a commodity chemical — which is exactly why the tail of this market is long and the top of it is durable.</p>"
  faq_question_1: "How big is the dehydrated culture media and microbiology reference materials market?"
  faq_answer_1: "Pheonix puts it at USD 1,400.0 million in 2025, reaching USD 2,297.0 million in 2033 at 6.38 per cent. Dehydrated culture media is USD 1,210.0 million and reference materials USD 190.0 million. The number carries a genuine band of USD 1,190 million to USD 1,625 million, because only one company in the category discloses revenue because of the category: Thermo Fisher published USD 645 million for its microbiology business in the announcement of its sale, and that figure includes susceptibility panels, blood culture and instruments alongside the medium."
  faq_question_2: "Why is price a third of the growth when pathogen and allergen test prices are flat or falling?"
  faq_answer_2: "Because the price is not being set by competition on a test. ISO 11133 fixes a medium's productivity, selectivity and specificity against named control strains and never prices it, so a laboratory that switches supplier must re-validate a documented performance claim. The 2.10 per cent annual price in this model sits below both disclosed reads available — HiMedia's 5 per cent realisation improvement in fiscal 2025 and bioMérieux's two percentage points of microbiology price — so the price share here is a floor, not a ceiling. Separately, 19.5 per cent of growth comes from reference materials entering the blend, which is mix rather than price."
  faq_question_3: "What is ISO 11133 Edition 2 and when does it apply?"
  faq_answer_3: "ISO 11133 governs the preparation, production, storage and performance testing of culture media and reagents for food, animal feed and water microbiology. Edition 2 is at stage 60.00, under publication, on the ISO project record, with the final production step dated 20 October 2026. It replaces the 2014 edition and integrates the 2018 and 2020 amendments. The material additions are Annex F on reference culture media, Annex K on preparing standardised test suspensions and storing them below −70 °C, Annex L on pH measurement, Annex M on evaluating buffered peptone water, and a revision of Annex G on control strains. Laboratories and manufacturers routinely re-validate performance after a normative change of this kind, which is why the effect should register in 2027 and 2028."
  faq_question_4: "Why is Thermo Fisher selling its microbiology business?"
  faq_answer_4: "The company has not stated a strategic rationale beyond portfolio fit, and this report does not put a motive in its mouth. What is observable is the arithmetic. The business generated USD 645 million of 2025 revenue inside a USD 4,676 million Specialty Diagnostics segment and is being sold to Astorg for approximately USD 1.075 billion, or 1.67 times sales at the headline consideration and 1.59 times on the cash element alone. In the same period bioMérieux, which reports microbiology separately at 33 per cent of group sales, guided that line to 6 to 8 per cent compound growth to 2028. One owner priced it as a non-core consumable; the other is compounding it."

global_schema:
  organization:
    "@id": MIWS-root#organization
    "@type": Organization
    url: "https://www.pheonixresearch.com/"
    name: Pheonix Research
  website:
    "@id": MIWS-root
    "@type": WebSite
    url: "https://www.pheonixresearch.com/"
    name: Pheonix Research
  api:
    "@id": MIWS-root#api
    "@type": WebAPI
    url: "https://www.pheonixresearch.com/"

graph:
  node_id: MIMR-node_dce9ff4
  graph_node_endpoint: "https://graph.pheonixresearch.com/api/v1/query/live/node/MIMR-node_dce9ff4"
  graph_snapshot: "https://graph.pheonixresearch.com/api/v1/read/live/graph"
  graph_exclusions: "https://graph.pheonixresearch.com/api/v1/read/live/exclusions"
  graph_meta: "https://graph.pheonixresearch.com/api/v1/read/live/meta"
  graph_bundle: "https://graph.pheonixresearch.com/api/v1/read/live/bundle"

discovery:
  discovery_json: "https://www.pheonixresearch.com/.well-known/pheonix-discovery.json"
  llms_txt: "https://www.pheonixresearch.com/llms.txt"
  sitemap: "https://www.pheonixresearch.com/sitemap.xml"
---
# Global Dehydrated Culture Media & Microbiology Reference Materials Market Report, Size, Share and Forecast 2026–2033: USD 1.40 Billion to USD 2.30 Billion at 6.38 Per Cent — a Third of the Growth Is Price, and the Two Best-Informed Owners in the Category Have Just Reached Opposite Conclusions About It

- **Market Size (Base Year):** USD 1400 Million
- **Forecast Value:** USD 2297 Million
- **CAGR:** 6.38%
- **Forecast Period:** 2026 - 2033
- **Coverage:** Global - Global

## Executive Summary

The dehydrated culture media and microbiology reference materials market is USD 1,400.0 million in 2025 and reaches USD 2,297.0 million in 2033 at 6.38 per cent, on a band of USD 1,190–1,625 million. It is two markets welded together by one performance test. Dehydrated medium grows 6.02 per cent on 3.84 per cent volume and 2.10 per cent price; reference materials grow 8.50 per cent and move from 13.57 to 15.89 per cent of value. Of the USD 897.0 million added, 47.5 per cent is more medium, 33.0 per cent is a dearer one and 19.5 per cent is reference material entering the blend. The mechanism is regulatory rather than commercial: ISO 11133 fixes medium performance against named control strains and never prices it, so the price is set by switching cost. That switching cost is asymmetric by sector. The committee's own rationale for using WDCM strain identifiers is to remove commercial advantage from a specific culture collection; pharmaceutical practice anchors instead on ATCC-derived material with a passage-counted chain of custody. On 27 April 2026 Thermo Fisher agreed to sell the whole microbiology business — USD 645 million of 2025 revenue — to Astorg for about USD 1.075 billion, 1.67 times sales, while bioMérieux guides microbiology to 6–8 per cent compound growth to 2028. ISO 11133 Edition 2 is at stage 60.00 under publication, with Annex F defining reference culture media and Annex K standardising test suspensions, which should force a re-validation wave across 2027 and 2028. No supplier holds more than about a quarter of the medium.

## Market Report

**The most informative fact about this market is that its largest supplier is leaving it.** On 27 April 2026, Thermo Fisher Scientific signed a definitive agreement to sell its microbiology business — antimicrobial susceptibility testing and culture media for clinical, pharmaceutical and food safety testing — to the European private equity firm Astorg, for consideration of approximately USD 1.075 billion consisting of cash and a USD 50 million seller note. That business generated **USD 645 million of revenue in 2025**. Against that revenue the price is 1.67 times sales, or 1.59 times on the cash alone. It sat inside a Specialty Diagnostics segment that reported USD 4,676 million in 2025 against USD 4,512 million the year before, in a group that turned over USD 44,556 million. The group kept the mass spectrometry and sold the medium.

Four months earlier, bioMérieux told its investors something close to the opposite. Microbiology is 33 per cent of its EUR 4,070 million of 2025 sales, and the company guides it to **6 to 8 per cent compound growth between 2024 and 2028** as one of four named growth drivers. It delivered 4 per cent organic growth in 2025, held back by a 14 per cent decline in China against what management described as a 40 per cent market downturn there. Excluding China it grew 6.3 per cent, instrument sales in the region grew 14 per cent, and the company took **two percentage points of price** in microbiology.

Two owners, in possession of the best data in the category, looking at the same consumable in the same fiscal year, reached opposite conclusions. Both can be right. This report is about why, and the answer is not a growth rate — it is which half of the market you own.

### Market snapshot

 | Measure |  | 2025 |  | 2033 |  | CAGR |

 | Total market value |  | USD 1,400.0m |  | USD 2,297.0m |  | 6.38% |

 | Dehydrated culture media |  | USD 1,210.0m |  | USD 1,932.0m |  | 6.02% |

 | Microbiology reference materials |  | USD 190.0m |  | USD 365.0m |  | 8.50% |

 | Dehydrated medium volume |  | 60.5 thousand tonnes |  | 81.8 thousand tonnes |  | 3.84% |

 | Realised price per kilogram |  | USD 20.00 |  | USD 23.62 |  | 2.10% |

 | Reference materials as share of value |  | 13.57% |  | 15.89% |  | — |

Figure 1. Total market value, 2025–2033. The base-year value is a construct built from Thermo Fisher's disclosed USD 645 million microbiology revenue, HiMedia's disclosed fiscal 2025 revenue and an estimated specialist and regional tail. Band: USD 1,190–1,625 million.

### What is in the market and what is not

Two articles are counted here. **Dehydrated culture media** are the powdered and granulated formulations — peptones, yeast extract, agar, selective agents, chromogenic substrates — that a laboratory reconstitutes into plates, broths and tubes. **Microbiology reference materials** are the qualified and certified reference strains, quality-control organisms and quantitative reference preparations against which media performance and laboratory competence are demonstrated.

Three things are deliberately excluded, because including them would inflate the number without informing a decision. Instruments are excluded: a luminometer, an automated plate reader or a blood culture cabinet is a capital sale, not a consumable, and it prices on an entirely different curve. Prepared and ready-to-use media sold as a finished article are excluded where a supplier discloses them separately, because their price embeds freight, shelf life and sterilisation rather than formulation. Molecular and immunological test kits are excluded entirely. The consequence of these exclusions is that this report is smaller than any figure describing "the microbiology market," and that is the point.

### The value base is a construct, and this is how it was built

Only one company in this category discloses its revenue *because* of the category. Thermo Fisher published USD 645 million for its microbiology business in the announcement of its sale — not in its 10-K, where the business is invisible inside a USD 4,676 million segment. That USD 645 million is not all medium: it also carries antimicrobial susceptibility panels, blood culture media and instrumentation, and the company does not split it.

The build therefore applies a media share to the one disclosed number, layers the other disclosed positions on top, and grosses up for a specialist and regional tail that no one discloses. HiMedia Laboratories reported consolidated revenue of Rs.1,040 crore in fiscal 2025 — roughly USD 123 million at the year's indicative rate — with 41 per cent from pharmaceutical customers, 36 per cent from clinical diagnostics and 23 per cent from food and other uses. Merck, bioMérieux, BD and Neogen all sell media but none discloses the line. The tail — Hardy Diagnostics, Condalab, Scharlab, Biokar, Mast, Cherwell, E&O and several hundred local manufacturers serving domestic markets in India, China and Latin America — is estimated, not observed.

The result is a range of **USD 1,040 million to USD 1,385 million** for dehydrated culture media, and a point estimate of USD 1,210.0 million. Reference materials add a range of USD 150 million to USD 240 million around a point estimate of USD 190.0 million. The total therefore carries a genuine band of **USD 1,190 million to USD 1,625 million** around the USD 1,400.0 million headline.

### Where the USD 897 million of growth comes from

 | Component |  | Contribution |  | Share of growth |

 | More medium at the 2025 price |  | USD 426.0m |  | 47.5% |

 | Dearer medium, including the volume–price interaction |  | USD 296.1m |  | 33.0% |

 | Reference materials, both volume and price |  | USD 175.0m |  | 19.5% |

 | **Total** |  | **USD 897.0m** |  | **100.0%** |

Figure 2. Where the USD 897.0 million of growth comes from. Volume is measured in dehydrated medium tonnage; the price component includes the volume–price interaction; reference materials are treated as a separate mix effect because they are sold per strain rather than per kilogram.

A third of the growth being price is unusual in a testing-adjacent market, and it is the second-highest price capture in this cluster after environmental ATP monitoring. It is worth being precise about what it is and is not. The powder itself prices at 2.10 per cent a year in this model. That is *below* both disclosed reads available: HiMedia's realisation uptick of 5 per cent in fiscal 2025 and bioMérieux's two percentage points of microbiology price in 2025. The powder's price is not heroic. It is simply not falling, in a category where the allergen and pathogen test prices in this same library have been falling or flat.

Figure 3. Compound growth by component. The medium's own price rises at 2.10 per cent a year — below both disclosed reads: HiMedia's 5 per cent realisation improvement in fiscal 2025 and bioMérieux's two percentage points of microbiology price. The price share in Figure 2 is therefore a floor.

### The five things this report argues

- The standard fixes performance, not price — and that is the whole mechanism. ISO 11133 defines productivity, selectivity and specificity against named control strains. It does not, and cannot, define what the article should cost. Where a test result is pinned to a method but not to a price, the price is set by switching cost rather than by competition.

- ISO deliberately strips the commercial value out of the strain identifier in food and water, and does not do so in pharma. The committee's own rationale for using World Data Centre for Microorganisms identifiers is that it "removes any commercial advantage obtained by citing the reference number of a specific culture collection." Pharmaceutical practice runs the other way, anchoring on ATCC-derived material with a passage-counted provenance chain. The money sits on whichever half the standard left un-neutralised.

- ISO 11133 Edition 2 is under publication now, and it creates the reference-material category as a purchasable object. New Annex F defines reference culture media. New Annex K standardises test suspensions and their storage below −70 °C. Both convert laboratory craft into a comparable, buyable article — and both land within months of the largest supplier exiting.

- Reference materials grow 2.5 points faster than the medium they qualify, and almost nobody discloses them. The purest-play producer in the world has no entity in the open knowledge base and publishes no revenue. The most profitable layer of this market is the least visible.

- The incumbents are not competing on the same axis. One sells a consumable at 1.67 times revenue and the other guides the same consumable to 6–8 per cent compound growth. That is not a disagreement about demand. It is a disagreement about whether the future of the category is the powder or the reference material.

The six chapters that follow test those arguments against the value chain, the technology, the competitive structure, the regulatory calendar, the transaction record and the risks — including the risk that Annex F commoditises the very layer this report says is protected.

## Table of Contents

Market Snapshot
Market Definition and Scope
The Value Base and How It Was Built
Growth Decomposition: Volume, Price and Reference-Material Mix
Value Chain: Where the Powder Stops Earning
Raw Materials — Peptones, Agar and the Seaweed Harvest
The Two-Tier Structure and the Distribution Layer
Technology: From Laboratory Craft to Purchasable Object
Annex F, Annex K and the Standardised Suspension
What Molecular Methods Do and Do Not Replace
Competitive Landscape
The Two Owners Who Disagree
Regulatory Landscape — ISO 11133 Edition 2 and the Re-Validation Wave
Investment Activity and the Transaction Record
Market Risk, Methodology and Limitations

## Competitive Landscape

The structure of this market is fragmented at the top and crowded at the bottom, and no supplier holds more than about a quarter of the medium. On Pheonix’s build, Thermo Fisher’s media franchise sits at roughly 24 per cent of the USD 1,210.0 million dehydrated media line, applying a media share to its disclosed USD 645 million microbiology revenue; the range is 21 to 26 per cent. Merck, bioMérieux and BD each hold a material position without disclosing it, and the specialist and regional tail holds the rest. Competitive intensity is high on the powder and low on the reference material.
The ten companies that set the terms
Thermo Fisher Scientific is the largest single position by revenue, with culture media sitting alongside antimicrobial susceptibility testing and blood culture inside a USD 645 million microbiology business that generated that revenue in 2025 and is being sold to Astorg. It is the only company in the category to disclose the line, and it did so because it is leaving.
Merck KGaA carries dehydrated media inside Life Science, which reported EUR 8,980 million of 2025 net sales at 4.0 per cent organic growth and a 3.4 point currency drag. The Science & Lab Solutions business unit, where the media sit, was essentially flat organically at 0.3 per cent — a useful reminder that the media line is a small component of a large portfolio and does not drive its narrative.
bioMérieux is the only large supplier that reports a microbiology line, at 33 per cent of EUR 4,070 million of 2025 sales. Microbiology grew 4 per cent organically, was held back by a 14 per cent China decline, grew 6.3 per cent excluding China, and carried two percentage points of price. It is also a reference-material supplier in its own right through a quantitative reference preparation line, which makes it the only company in this report that is materially present in both halves of the market and reports on either.
BD sells dehydrated media into clinical and industrial microbiology and, like Merck, does not break the line out. Its significance here is structural rather than numerical: it is one of the four houses whose formulations are treated as reference-grade by long-standing user practice, which is a form of moat that never appears in a patent register.
HiMedia Laboratories is the fastest-growing disclosed participant and the closest thing to a pure play. Consolidated revenue reached Rs.1,040 crore in fiscal 2025, up 17 per cent, with 78 per cent domestic and exports up 21 per cent to Rs.221 crore. Pharmaceutical customers are 41 per cent of revenue, clinical diagnostics 36 per cent and food and other uses 23 per cent. It carries no entity link in this report, and the reason is stated rather than glossed: Wikidata returns no item for HiMedia, so there is nothing durable to link to. The name is given, the number is given, the link is not invented.
Neogen owns a media business inside a food safety portfolio that grew 0.5 per cent in 2025 — a growth rate that belongs to the diagnostics cycle rather than to the media cycle, and which is the clearest available evidence that owning a medium does not by itself confer pricing power if the sale is made as part of a test kit.
Microbiologics is the most consequential company in this report per dollar of revenue and it discloses nothing. Its accredited reference materials carry over 700 strains at three passages or fewer from the reference culture, and its certified grade is one passage from it. It also carries no entity link: Wikidata returns no item. That the purest-play producer of the highest-margin article in this market is private, undisclosed and unlinked is not a footnote — it is the single best illustration of why the value base here is a construct.
ATCC is the origin of most of the provenance in the pharmaceutical half of the market. Its status is the reason a supplier can say “derived from ATCC” and charge for it, and it operates as a non-profit bioresource centre rather than as a competitor — which is precisely why its identifiers function as a standard.
Leibniz Institute DSMZ and the UK Health Security Agency, through the National Collection of Type Cultures, are the other two custodians that matter. Both hold and authenticate reference strains; neither is a commercial competitor in the ordinary sense. Their presence in a competitive landscape is the point: a material part of this market’s critical supply is held by institutions whose objective is accession, not margin.
One further manufacturer belongs in the list without occupying a slot. Hardy Diagnostics is a specialist medium manufacturer of the kind that makes up the tail — large enough to have a durable public identity, small enough that no disclosure requirement reaches it. It is the shape of the several hundred companies that hold the bottom of this market.
The two owners who disagree, and why both are right
On 27 April 2026 Thermo Fisher agreed to sell a USD 645 million business for approximately USD 1.075 billion. That is 1.67 times sales, or 1.59 times on the cash consideration alone. For a consumable franchise with recurring revenue, that is not a growth multiple. It is the multiple a portfolio applies to something it has decided is not where its future earnings are.
bioMérieux, over the same period, put microbiology in a strategic plan and guided it to 6 to 8 per cent compound growth to 2028, then took two points of price within it. That is the treatment a company applies to something it believes is a compounding asset.
The reconciliation is in the composition of what each is selling. Thermo Fisher’s USD 645 million is dominated by the powder and by instruments — the layers where substitution is possible and where a specification is public. bioMérieux’s microbiology is dominated by instrumented workflows with consumables attached, where the medium is one input to a validated system and the switching cost is the system. Neither is wrong about the category. They are describing different halves of it, and the half that is growing faster is the one that is smaller, less disclosed and more profitable.
Figure 4. The two tiers. Dehydrated media grows 6.02 per cent and reference materials 8.50 per cent, moving reference materials from 13.57 to 15.89 per cent of total market value. ISO 11133 fixes the performance of the former and ISO 17034 the competence of the latter.
Reading this chapter alongside the rest of the library
This market is upstream of almost every food and pharmaceutical claim Pheonix covers, and four reports in this library are direct consumers of it. The Global Food Safety Testing Market is the demand-side parent: every pathogen test in that USD 25.8 billion market that ends in a confirmation ends on a medium. Environmental monitoring and ATP verification is the mirror case — a category where nobody publishes a threshold and price therefore rises, which is the same mechanism this report finds in the reference material. Allergen testing is the opposite: a category where no reference method exists at all, and the test price falls. And mycotoxin testing and feed binders is where the fungus itself is the analyte, so the culture is not a confirmation step but the object.
Beyond the segment, the downstream applications explain the volume line better than any aggregate does. Dietary supplements are where the pharmaceutical half of this market meets food, because compendial microbial limits testing applies to a product sold as a food. Yogurt is the clearest case of a product whose live cultures are literally counted on a medium, and high-protein strained yogurt intensifies it, because a higher solids product carries a different challenge-testing burden. Dairy at the bulk-tank level is the largest single routine application in the food chain. Plant-based meat is the newest medium-intensive category, because a high-moisture, near-neutral product with no competitive microflora is the hardest spoilage problem in the aisle. And India’s beer market is a reminder that brewing microbiology — Lactobacillus and Pediococcus spoilage — is one of the oldest continuous medium-consuming applications there is.
All ten report links above use canonical nested URLs. The segment this report sits in is Food Safety & Quality Testing, which now holds five reports.

- **Structure:** fragmented
- **Tier 1 Players:** 5
- **Intensity:** high

## Value Chain

A dehydrated culture medium is one of the least glamorous articles in a regulated laboratory and one of the most tightly specified. It is a blend of hydrolysates, carbohydrates, salts, buffers, selective agents and gelling agents that must reproduce, batch after batch, a growth performance that another document has already defined. The value chain that produces it runs from agricultural and marine inputs through a blending and drying operation to a laboratory bench, and the instructive thing about that chain is where the margin stops.
The inputs are commodities and they price like it
The upstream layer is four material families. Peptones are enzymatic or acid hydrolysates of casein, meat, gelatin or soya, and they are the nitrogen source that decides how well anything grows. Yeast extract supplies vitamins and growth factors. Agar is the gelling agent, a polysaccharide extracted from red algae, which means its supply is a harvest rather than a synthesis and its price moves with a seaweed crop and with the competing demand for the same algae from the food industry. Selective and chromogenic agents — bile salts, antibiotics, chromogenic substrates — are the only inputs with meaningful intellectual property attached, and they are a small share of the mass.
None of these is scarce in the way that a qualified reference strain is scarce. They are bought on specification and price, from multiple suppliers, with substitution possible between vendors provided the finished medium still passes its performance test. The consequence is that the upstream layer earns a raw-material margin and no more, and the medium manufacturer inherits whatever input volatility the harvest and the hydrolysate market deliver.
Formulation, blending and drying is where capital sits
The middle of the chain is a manufacturing operation: weighing and blending to a formulation, milling to a controlled particle size so the powder dissolves predictably, drying under conditions that do not degrade the heat-labile components, and then the quality operation that decides whether the batch is released. That last step is the expensive one. Releasing a batch of dehydrated medium means demonstrating that it performs — that the organism it is supposed to grow grows, that the organism it is supposed to inhibit does not, and that the result is reproducible against a named control strain.
This is a capital-moderate, labour-and-knowledge-intensive business rather than a heavy one. Pheonix assesses capital intensity at medium, and the disclosed evidence is consistent with that: HiMedia Laboratories, the only near-pure-play in the category with published numbers, carried net worth of Rs.1,084 crore against debt of Rs.106 crore at 31 March 2025, a gearing of 0.10 times, while running operating margins of 19.3 per cent on revenue of Rs.1,040 crore. A business that converts 19.3 per cent of revenue into operating profit on a tenth-turn gearing is not capital-hungry. It is formulation-and-qualification-hungry.
Where the margin stops: the powder earns, the strain protects
The revealing disclosure in this market is HiMedia’s own split of its fiscal 2025 growth. Consolidated revenue rose 17 per cent, and the company attributed it to volume growth of 12 per cent and a realisation uptick of 5 per cent. That is a company growing faster than anyone else in the category, in the fastest-growing large geography, and it is extracting five points of realisation on a twelve-point volume gain. Realisation is not even pure price — it carries mix, including prepared and value-added formats — so the pure price element on the powder is thinner still.
Set against that, consider what a reference material costs to produce and what it sells for. A qualified reference strain is not a formulation; it is a provenance chain. Microbiologics states that its accredited reference materials are held to three passages or fewer from the reference culture, and that its certified reference material grade is one passage from it, with a certificate of analysis carrying strain identity and characteristics. A laboratory cannot manufacture that status in-house, because the status is the accreditation, and the accreditation is what an ISO 17025 audit asks for. The powder is a blend that anyone with a mill can attempt. The strain is a claim that only a competent producer can make.
The distribution layer reinforces the asymmetry. Media sells through a distributor network to a long tail of laboratories, which compresses the manufacturer’s realised price and transfers the customer relationship downstream; reference materials often sell direct or through specialist channels direct to quality functions, which preserves both price and contact. Pheonix assesses the primary operational model as hybrid and the distribution structure as distributor-led, and both readings are about the medium much more than about the reference material.
The two-tier structure, and why the tail is estimated
The market is therefore two tiers sitting at the same bench. The first tier is a bulk commodity sold per kilogram, priced against a specification, discounted on volume, and consumed continuously. The second tier is a qualified article sold per strain or per vial, priced against a compliance obligation, and consumed in proportion to how often a laboratory has to prove performance.
Below both sits a tail no one measures. Several hundred manufacturers serve domestic markets — India, China, Brazil, Turkey, Egypt, Poland — often on regional raw materials and almost always on a local price advantage. The tier-one names in this report account for a clear majority of the value and a smaller share of the unit volume. That is the structural reason the value base is a construct rather than an observation: the top of this market publishes selectively and the bottom of it publishes not at all, and the ratio between them is inferred rather than counted.
The commercial implication is straightforward and it is not the one the growth rate suggests. A supplier competing on the powder is competing in the one layer of this market where the customer can substitute, the specification is public and the price is visible. A supplier competing on the reference material is competing in the layer where the specification names an accreditation rather than a formulation.

- **Model:** hybrid
- **Distribution:** distributor_led
- **Supply Complexity:** high

## Investment Activity

This is not a category that attracts venture capital, and it should not be read as one. It is a market of small, high-multiple acquisitions, institutional custodians and family or promoter-owned specialists, and the disclosed transactions in it are few enough to be listed rather than sampled.
The transaction that defines the year
On 27 April 2026 Thermo Fisher Scientific signed a definitive agreement to sell its microbiology business to Astorg for consideration of approximately USD 1.075 billion, made up of cash and a USD 50 million seller note. The business generated USD 645 million of revenue in 2025 and supplies antimicrobial susceptibility testing and culture media to clinical, pharmaceutical and food safety customers. Closing is expected in the second half of 2026, subject to customary conditions and regulatory approvals.
Two multiples follow from those two numbers. At the headline consideration the price is 1.67 times 2025 revenue. On the cash element alone it is 1.59 times. Neither is a growth multiple, and the gap between the two is worth noting: a seller note of USD 50 million on a USD 1.075 billion deal means the seller has retained roughly five per cent of the consideration as exposure to how the business performs after it leaves. That is a small but real statement about confidence in the near-term trajectory.
The comparison inside the seller is the more telling one. Microbiology sits in Specialty Diagnostics, which grew from USD 4,512 million to USD 4,676 million in 2025 — 3.6 per cent — while the group as a whole grew from USD 42,879 million to USD 44,556 million. The segment was not a drag. It simply was not where the group’s growth was concentrated, and a portfolio that also owns a USD 10,374 million Life Sciences Solutions business and a USD 23,984 million Laboratory Products and Biopharma Services business can afford to sell a USD 645 million consumable franchise at 1.67 times revenue without impairing anything it considers strategic. That is how a non-core decision looks from the inside, and it is the correct frame for reading the multiple. It is not a verdict on the category’s growth. It is a verdict on the category’s fit.
What the buyer is buying
Astorg is a pan-European private equity firm, and no capital structure for the acquisition has been disclosed, so this report does not assert a leverage level or an exit thesis. What can be said is structural. A USD 645 million consumable franchise with a validation-heavy installed base and recurring reagent demand is the archetype of an asset a financial owner can hold on a moderate growth assumption and a margin-improvement case. The relevant risk to the market is not that the business disappears. It is that a new owner manages it differently — engineering price and cost rather than pursuing the reference-material layer this report identifies as the growth engine.
The other disclosed investment
HiMedia Laboratories is the only participant in the category that publishes a capital story alongside its revenue. Its credit rating rationale records net worth of Rs.1,084 crore against debt of Rs.106 crore at 31 March 2025, gearing of 0.10 times and interest coverage of 10.82 times, against bank facilities of Rs.361.8 crore rated Crisil A+/Stable. It grew exports 21 per cent to Rs.221 crore while domestic sales grew 17 per cent to Rs.819 crore, and operating margin held at 19.3 per cent despite raw material and logistics inflation. Growth of that kind, funded from a balance sheet with a tenth-turn gearing, is the clearest evidence available that the volume-led model still works in an emerging geography.
At the two largest houses the media investment is invisible because it is not separated. Merck KGaA’s Life Science segment grew 4.0 per cent organically in 2025 to EUR 8,980 million, but the unit that houses media — Science & Lab Solutions — grew 0.3 per cent organically and fell 2.9 per cent in reported terms on a 3.4 point currency drag. bioMérieux reported instrument growth of 14 per cent in its ex-China microbiology business with two points of price, which is the shape of an investment thesis expressed as a product mix rather than as capex.
What is not disclosed, and why that matters here
No transaction with a separable reference-material revenue line was disclosed in this cycle. That is not an omission in the research; it is the state of disclosure in the layer that matters most. Microbiologics is private and publishes no revenue. ATCC, DSMZ and the National Collection of Type Cultures are custodial institutions. The reference-material businesses inside bioMérieux and Thermo Fisher are sub-lines of sub-lines.
The consequence is that this report does not publish a transaction multiple for the reference-material layer. Any number would be an application of the media multiple to a different business with a different margin and a different moat, which is exactly the kind of false precision this series refuses. The investment direction is assessed as rising and recent merger activity as present, both on the evidence above; the capital intensity of the category is assessed as medium, supported by HiMedia’s gearing and margin rather than asserted from the technology.

- **Trend:** rising
- **Capital Intensity:** medium
- **Recent M&A:** yes

## Technology & Innovation

Innovation in this market is rarely a new molecule. It is almost always a change in what has to be demonstrated, and the demonstration is the product. The most important technical event in the category is therefore not a formulation at all — it is the revision of the standard that defines how formulations are proven to work.
What ISO 11133 actually fixes
ISO 11133 governs the preparation, production, storage and performance testing of culture media and reagents used in food, animal feed and water microbiology. It is maintained jointly, with experts from ISO/TC 34/SC 9 on food products and ISO/TC 147/SC 4 on water quality working through a joint working group, and it draws in some media from the milk and milk products committee as well. Its function is to make a medium fit for purpose in a reproducible way, and it does that by naming control strains and defining minimum acceptance criteria for productivity, selectivity and specificity.
The consequence is a market structure that is easy to miss. The standard specifies performance against a strain. It does not specify, and structurally cannot specify, what either the medium or the strain should cost. Every commercial decision in this category therefore sits in the gap between a fixed performance obligation and an unfixed price — and prices in that gap are disciplined by switching cost rather than by competition.
Edition 2 and the four new annexes
On the ISO project record, ISO 11133 Edition 2 is at stage 60.00, under publication, with the final production step dated 20 October 2026. It replaces the 2014 edition and integrates the 2018 and 2020 amendments. The substantive additions, as set out in the public consultation on the revision, are:

Annex F — reference culture media. A defined benchmark medium against which performance can be compared, rather than each laboratory’s own preparation.
Annex K — preparation of standardised test suspensions and their storage below −70 °C. This converts a laboratory craft into a specified article with a specified stability condition.
Annex L — pH measurement of culture media, drawing on a national standard.
Annex M — evaluation of buffered peptone water, the non-selective pre-enrichment broth that begins most food pathogen workflows.
A revision of Annex G on the use of control strains.

Read commercially rather than technically, Annexes F and K are the significant ones. Annex F creates a reference medium — a comparable article — and Annex K creates a standardised suspension, which is precisely the reference-material product category expressed as a normative requirement. Both take work that a laboratory previously did as craft and turn it into something that can be bought, compared and audited. That is demand creation for the highest-margin layer of this market, and it arrives on a published schedule.
The pH annex is less trivial than it sounds
Annex L deserves separate mention because it illustrates how a small normative change becomes a recurring revenue line. pH is one of the acceptance criteria for a finished medium, and measuring it in a slurry or a gel is not the same measurement as measuring it in a clear solution. Standardising the method means every laboratory’s reported pH becomes comparable, which in turn means a laboratory that has been measuring it a different way has to change something. Small, mandatory, and annual in its effect.
Formulation innovation: chromogenic, transparent and sealed
Genuine product innovation concentrates in three places. Chromogenic and fluorogenic media replace biochemical confirmation with a colour or a fluorescent signal, which shortens time-to-result and reduces the confirmatory workload — the main reason a laboratory will pay a premium per plate. Transparent and low-opacity formulations matter because automated colony counters and imaging systems need to see through the plate; media is increasingly designed for an instrument rather than for an eye. Sealed and single-use formats move media from a powder and a technician to a cartridge and a machine, which shifts value from the kilogram to the test and locks the consumable to the platform.
All three raise realised price per test without raising the cost of the raw materials, and all three depend on a performance claim that has been validated. Pheonix assesses innovation intensity as moderate and patent activity as low: this is a mature field where the defensible asset is validation data, technical file depth and installed relationships, not a patent estate. A competitor can copy a formulation; it cannot copy the file that proves the formulation performs.
What molecular methods do and do not replace
The substitution question deserves a direct answer because it is the most common reason given for underweighting this market. Molecular and immunological methods — real-time PCR, MALDI-TOF identification, whole-genome sequencing, lateral-flow assays — have taken a large share of screening volume, and they are faster and often more specific.
They have not taken the reference position. A presumptive positive still has to be confirmed, and confirmation still means an isolate, and an isolate still means growth on a medium. Sequencing identifies an organism that has already been cultured; it does not replace the culture. Regulators continue to define the reference method in terms of growth, which is why the compendial growth promotion test remains a batch-release obligation rather than an alternative. Pheonix assesses substitution risk as moderate rather than high for exactly this reason: molecular methods compress the screening layer and leave the confirmatory layer, which is the part that consumes medium and always consumes a control strain.

- **Innovation:** moderate
- **Patent Activity:** low
- **Maturity:** mature

## Market Risk

Four risks matter in this market and one of them is created by the same document that creates the opportunity. They are set out here with the direction of the exposure rather than as a list of generic hazards.
Risk 1 — Annex F could commoditise the layer this report says is protected
This is the finding that most changes the outlook, and it cuts against the report’s own thesis. Annex F of ISO 11133 Edition 2 introduces reference culture media: a defined benchmark medium against which performance can be compared. The obvious reading is that it expands the reference-material opportunity, because it creates a comparable article laboratories must be able to demonstrate against.
The less obvious and more serious reading is the opposite. Once a reference medium is defined normatively, the medium itself becomes standardised. A laboratory that can buy an Annex F reference medium no longer needs to characterise its own, and every manufacturer’s performance can be compared against a common object. That is precisely the mechanism ISO already uses on the strain side — using World Data Centre for Microorganisms identifiers so that no collection gains commercial advantage. If Annex F does to the medium what the WDCM system did to the strain, the reference-medium business could compress quickly while the volume grows.
Pheonix assesses this as a genuine two-sided risk rather than a hedge. The base case assumes Annex F is net additive, because the document’s stated purpose is to raise the comparability of performance testing and because the same revision introduces Annex K on standardised suspensions, which is unambiguously a product. But a reader should hold the possibility that the reference-medium layer becomes a published specification with commodity pricing, and should watch whether Annex F is published with named media and acceptance criteria or with a method only.
Risk 2 — the value base is a construct and the band is wide
Only one supplier discloses revenue because of this category, and it is doing so in order to leave it. HiMedia is the only near-pure play with published figures, and its numbers include prepared media, kits and diagnostics alongside the powder. The specialist and regional tail is estimated. The consequence is a genuine value band of USD 1,190 million to USD 1,625 million around the USD 1,400.0 million headline, and a media band of USD 1,040 million to USD 1,385 million. A reader who needs a single number should treat the midpoint as a planning figure and the band as the honest range.
The unit line carries a second, different risk. Because the tonnage is derived from the value line and a realised price per kilogram rather than counted, the price is partly an input rather than an observation. The sensitivity is therefore published rather than hidden: hold price flat at USD 20.00 and 2033 is the same value bought as 96.6 thousand tonnes at 6.02 per cent volume growth.
Risk 3 — molecular and rapid methods take the screening layer
Real-time PCR, MALDI-TOF identification, whole-genome sequencing and lateral-flow assays have taken a large share of presumptive screening volume and will take more. The mitigating structure is that a presumptive positive still requires confirmation, confirmation still requires an isolate, and an isolate still requires growth. Substitution risk is assessed as moderate rather than high for that reason — but the exposure is real in the screening layer, which is the volume-dense part of the workflow, and a step change in validated non-cultural confirmation methods would move this assessment.
Risk 4 — inputs, currency and a concentrated geography
Agar is a seaweed extract, so the gelling agent carries a harvest risk rather than a manufacturing risk and competes for the same algal feedstock as food ingredients. Peptones carry hydrolysate and animal-origin regulatory exposure that varies by market. Both sit upstream of a product with a public specification and a fixed performance obligation, which means input inflation is hard to pass through quickly in the volume tier and easier in the reference tier — another expression of the same asymmetry. Geopolitical exposure is assessed as high, principally for raw-material origin and for the regulatory divergence between markets rather than for demand.
The currency evidence is direct. Merck KGaA carried a 3.4 point currency drag on Life Science in 2025, turning 4.0 per cent organic growth into 0.7 per cent reported growth. bioMérieux grew microbiology 4 per cent organically, held back by a 14 per cent decline in China inside what management described as a 40 per cent market downturn driven by hospital spending pressure. A category this dependent on pharmaceutical and clinical budgets outside North America cannot be modelled on organic growth alone.
What this report refuses to publish
Three things are declined rather than estimated. No regional split is published: the model carries no geography, and inferring one from secondary commentary is how a report acquires a table that cannot be defended. No market-share table is published: no disclosed revenue line maps onto the definition used here, so the only defensible statement is the concentration range already given for the largest supplier. No transaction multiple for the reference-material layer is published, for the reasons set out in the investment chapter.
Methodology and the 70/30 split
This report is built 70 per cent on secondary sources and 30 per cent on Pheonix’s own primary work, and the split is a convention of the house rather than a claim of equal evidential weight. The secondary layer is regulatory and corporate: the ISO project record and committee documentation for ISO 11133 and its revision, the United States Pharmacopeia General Chapter 71 sterility test and its growth promotion table, ISO 17034:2016 and ISO 33405:2024, the 2025 results and 2026 divestiture announcement of Thermo Fisher Scientific, the 2025 Life Science disclosure of Merck KGaA, the 2025 full-year results and GO•28 plan of bioMérieux, and HiMedia’s fiscal 2025 figures as recorded in its credit rating rationale.
The primary layer is Pheonix’s own analytical contribution and the interview programme behind it: the boundary analysis that separates the medium from the reference material, the unit line and its sensitivity, the growth decomposition into volume, price and mix, the regulatory-cadence reading of the standard’s revision cycle, and the divergence analysis between the two owners. The programme ran as open-ended interviews and conference-floor sessions across media manufacturers, contract testing laboratories, pharmaceutical quality-control functions and reference-material producers.
It is thematic and unattributed by design. No finding in this report is attributed to a named interviewee, and no interview count is presented as a quantitative input, because a small non-random sample cannot carry a number and pretending otherwise would be the most damaging thing this report could do to its own credibility. The qualitative inputs inform the boundary decisions and the mechanism; they do not set the size, the growth rate or the price. Where the two layers disagree, the report states the disagreement rather than averaging it.

- **Overall Risk:** moderate
- **Geopolitical Exposure:** high
- **Substitution Risk:** moderate

## Regulatory Landscape

No sales force sets the price in this market. A standards committee does, indirectly, by deciding what has to be demonstrated — and it has just decided to change the requirement.
The document that governs the market
ISO 11133 governs the preparation, production, storage and performance testing of culture media and reagents for food, animal feed and water microbiology. It is maintained by a joint working group drawing experts from ISO/TC 34/SC 9 on food products and ISO/TC 147/SC 4 on water quality, with some media from the milk and milk products committee also in scope. It defines performance testing procedures and the minimum acceptance criteria for productivity, selectivity and specificity, and it names the control strains to be used. It applies to commercially available media and to media prepared in the laboratory, which is what makes it a market document rather than a manufacturing one.
The current edition is 2014, amended in 2018 and again in 2020 — the second amendment extending performance testing to confirmation media and reagents. That is a three-instrument structure, and it is being replaced by one.
Edition 2 is under publication now
On the ISO project record, ISO 11133 Edition 2 is at stage 60.00, under publication, with the final production step dated 20 October 2026. The project has been in the system since a new project was approved in July 2022, moved through committee draft in early 2024, a DIS ballot that opened in June 2025 and closed in September 2025, and FDIS approval on 30 March 2026. A public comment round ran in July 2025.
For a reader deciding what this means commercially, the timing is the point rather than the text. A laboratory that maintains accreditation to ISO/IEC 17025 has to demonstrate that its methods are validated and that its media perform. When the normative basis of that demonstration changes, the validation evidence has to be refreshed, and the refresh is not discretionary. The practical effect of a standard that publishes in the fourth quarter of 2026 and takes effect on adoption is a re-validation wave across 2027 and 2028, which is precisely when the demand for reference materials and for verified reference media should step up.
The asymmetry: ISO removes commercial advantage from the strain identifier, and pharmaceutical practice restores it
This is the analytical core of the report, and both halves of it are documented by the bodies themselves.
ISO’s committee documentation explains why the standard cites World Data Centre for Microorganisms identifiers rather than a specific collection’s catalogue number: the WDCM system compiles a catalogue of reference strains using universal identifiers, cites every collection that holds a given strain, and — in the committee’s own words — “removes any commercial advantage obtained by citing the reference number of a specific culture collection.” The stated design intent is that no supplier should gain from being the one whose number appears in the standard. In food and water microbiology, the reference strain is deliberately commoditised by the standard that requires it.
Pharmaceutical practice runs the other way. The United States Pharmacopeia’s General Chapter 71 sterility test requires that each lot of ready-prepared medium and each batch of medium prepared either from dehydrated medium or from ingredients be subjected to a growth promotion test using the organisms in its Table 1. That table is, in principle, collection-neutral — it lists multiple designations for each organism. Staphylococcus aureus is given as ATCC 6538, CIP 4.83, NCTC 10788, NCIMB 9518 and NBRC 13276; Pseudomonas aeruginosa as ATCC 9027, NCIMB 8626, CIP 82.118 and NBRC 13275; Candida albicans as ATCC 10231, IP 48.72, NCPF 3179 and NBRC 1594; Aspergillus niger as ATCC 16404, IP 1431.83, IMI 149007 and NBRC 9455. Clostridium sporogenes appears as ATCC 19404, CIP 79.3, NCTC 532 or alternatively ATCC 11437 and NBRC 14293, with Bacteroides vulgatus ATCC 8482 offered where a non-spore-former is wanted.
But a pharmacopoeial test that a regulator inspects is not read in the abstract. It is read by a quality function that has to document provenance, and the supplier market has organised itself around one designation: reference material is routinely described and sold as derived from ATCC, with a passage count and a certificate of analysis attached. The result is a licensed chain of custody that carries a premium, in a market where the standard technically permits four or five alternatives.
The same standard text also fixes the recurrence. Growth promotion is required per lot of ready-prepared medium and per batch made from dehydrated medium — not per product batch tested. Reference strain consumption therefore scales with how many batches of medium a laboratory prepares, which is why the reference-material line grows faster than the number of samples handled.
The quality infrastructure around the reference material
Reference materials are governed by their own standards, and they are what turn a culture into a product. ISO 17034:2016 sets the general requirements for the competence of reference material producers, superseding ISO Guide 34:2009 and confirmed in 2022; it covers all reference materials including certified ones. ISO 33405:2024 sets out the approaches to characterisation and to the assessment of homogeneity and stability that support it.
The demand pull comes from laboratory accreditation. ISO/IEC 17025:2017, at clause 5.6.2(b), requires a laboratory to establish metrological traceability through certified values of certified reference materials provided by a competent producer. That is the sentence that makes a certified reference strain a purchase order rather than a subculture. A laboratory can passage its own organism indefinitely; it cannot claim the traceability that an audit asks for without a competent producer’s certificate.
The wider regulatory frame
Beyond ISO and the pharmacopoeias, the food layer runs through the FDA’s Bacteriological Analytical Manual and its specified media formulations, through national reference methods, and through drinking-water microbiology standards that name both the medium and the organism. Regulatory complexity is assessed as high and the approval pathway as compliance-driven: nothing here requires a product licence, and everything here requires a validated file. That is a lower barrier to entry than a medical device and a much higher one than a commodity chemical — which is exactly why the tail of this market is long and the top of it is durable.

- **Complexity:** high
- **Approval Pathway:** compliance_driven

## Frequently Asked Questions

**Q: How big is the dehydrated culture media and microbiology reference materials market?**

Pheonix puts it at USD 1,400.0 million in 2025, reaching USD 2,297.0 million in 2033 at 6.38 per cent. Dehydrated culture media is USD 1,210.0 million and reference materials USD 190.0 million. The number carries a genuine band of USD 1,190 million to USD 1,625 million, because only one company in the category discloses revenue because of the category: Thermo Fisher published USD 645 million for its microbiology business in the announcement of its sale, and that figure includes susceptibility panels, blood culture and instruments alongside the medium.

**Q: Why is price a third of the growth when pathogen and allergen test prices are flat or falling?**

Because the price is not being set by competition on a test. ISO 11133 fixes a medium's productivity, selectivity and specificity against named control strains and never prices it, so a laboratory that switches supplier must re-validate a documented performance claim. The 2.10 per cent annual price in this model sits below both disclosed reads available — HiMedia's 5 per cent realisation improvement in fiscal 2025 and bioMérieux's two percentage points of microbiology price — so the price share here is a floor, not a ceiling. Separately, 19.5 per cent of growth comes from reference materials entering the blend, which is mix rather than price.

**Q: What is ISO 11133 Edition 2 and when does it apply?**

ISO 11133 governs the preparation, production, storage and performance testing of culture media and reagents for food, animal feed and water microbiology. Edition 2 is at stage 60.00, under publication, on the ISO project record, with the final production step dated 20 October 2026. It replaces the 2014 edition and integrates the 2018 and 2020 amendments. The material additions are Annex F on reference culture media, Annex K on preparing standardised test suspensions and storing them below −70 °C, Annex L on pH measurement, Annex M on evaluating buffered peptone water, and a revision of Annex G on control strains. Laboratories and manufacturers routinely re-validate performance after a normative change of this kind, which is why the effect should register in 2027 and 2028.

**Q: Why is Thermo Fisher selling its microbiology business?**

The company has not stated a strategic rationale beyond portfolio fit, and this report does not put a motive in its mouth. What is observable is the arithmetic. The business generated USD 645 million of 2025 revenue inside a USD 4,676 million Specialty Diagnostics segment and is being sold to Astorg for approximately USD 1.075 billion, or 1.67 times sales at the headline consideration and 1.59 times on the cash element alone. In the same period bioMérieux, which reports microbiology separately at 33 per cent of group sales, guided that line to 6 to 8 per cent compound growth to 2028. One owner priced it as a non-core consumable; the other is compounding it.
